Prognostic variables for patients with stage III malignant melanoma

被引:0
|
作者
Messaris, EG
Konstadoulakis, MM
Ricaniadis, N
Leandros, E
Androulakis, G
Karakousis, CP
机构
[1] Hippokrateio Hosp, Surg Res Lab, Propaedeut Surg Clin A, Athens, Greece
[2] Roswell Pk Canc Inst, Dept Surg Oncol, Buffalo, NY 14263 USA
关键词
malignant melanoma; stage III; prognostic factors;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To evaluate the prognostic factors for patients with stage III malignant melanoma and to identify patients at high risk of developing recurrent disease who may benefit from adjuvant therapy. Design: Retrospective study. Setting: Specialist hospital, USA. Subjects: 130 patients with stage III malignant melanoma (according to the TNM classification), treated at the Roswell Park Cancer Institute between 1970 and 1992. Main outcome measures: Survival and prognostic factors on multivariate analysis. Results: Four factors were independent prognostic indicators for patients with stage III malignant melanoma: age >51 years (p = 0.008), >3 involved lymph nodes, (p = 0.03), the site of the primary tumour on head or trunk, (p = 0.007), and the presence of palpable lymph nodes (p = 0.004). Conclusion: These prognostic factors help us to stratify patients into low and high-risk groups. High-risk patients may benefit from more aggressive adjuvant therapy in future trials of treatment of melanoma.
引用
收藏
页码:233 / 239
页数:7
相关论文
共 50 条
  • [41] Prognostic factors and molecular staging of patients with malignant melanoma
    Kim, CJ
    Shivers, S
    Li, W
    Turner, J
    Cruse, CW
    Messina, J
    Glass, F
    ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (01) : S18 - S18
  • [43] DNA PLOIDY AND S-PHASE IN PRIMARY MALIGNANT-MELANOMA AS PROGNOSTIC FACTORS FOR STAGE-III DISEASE
    KARLSSON, M
    BOERYD, B
    CARSTENSEN, J
    KAGEDAL, B
    BRATEL, AT
    WINGREN, S
    BRITISH JOURNAL OF CANCER, 1993, 67 (01) : 134 - 138
  • [44] Sensitivity and prognostic Significance of circulating Tumor DNA (ctDNA) correlates with established Biomarkers in Stage I to III Malignant Melanoma
    Heber, M.
    Bohne, A. -S.
    Axt, F.
    Kaehler, K. C.
    von Bubnoff, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 33 - 33
  • [45] Sensitivity and Prognostic Significance of Circulating Tumor DNA (ctDNA) Correlated to Established Biomarkers in Stage I to III Malignant Melanoma
    Bohne, A. S.
    Heber, M. M.
    Axt, F.
    Von Bubnoff, N.
    Kaehler, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 84 - 85
  • [46] Impacts of skeletal muscle on survival in resected stage III malignant melanoma
    Youn, S.
    Eurich, D. T.
    McCall, M. D.
    Walker, J.
    Smylie, M.
    Sawyer, M. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S878 - S879
  • [47] Low-dose adjuvant interferon for stage III malignant melanoma
    Inman, JL
    Russell, GB
    Savage, P
    Levine, EA
    AMERICAN SURGEON, 2003, 69 (02) : 127 - 130
  • [48] Radioimmunoscintigraphy in patients with early stage cutaneous malignant melanoma
    Blend, MJ
    Hyun, H
    Patel, B
    Sullivan, K
    Salk, D
    JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (02) : 252 - 257
  • [49] SURVIVAL OF PATIENTS WITH STAGE IA MALIGNANT-MELANOMA
    KONSTADOULAKIS, M
    KARAKOUSIS, CP
    WALSH, D
    RICANIADIS, N
    SURGICAL ONCOLOGY-OXFORD, 1995, 4 (02): : 101 - 104
  • [50] PHASE-II EVALUATION OF AMSA IN PATIENTS WITH STAGE III-IV MALIGNANT-MELANOMA
    FUKS, JZ
    VANECHO, DA
    AISNER, J
    SCHIPPER, H
    LEVITT, M
    WIERNIK, PH
    CANCER TREATMENT REPORTS, 1982, 66 (05): : 1237 - 1238